Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Boyle

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 21, 2014
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrierJung Soo Suk, Anthony J Kim, Kanika Trehan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Journal of Medical Genetics|December 13, 2006
Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosisKitti Buranawuti, Michael P Boyle, Suzanne Cheng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2011
N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticlesJung Soo Suk, Nicholas J Boylan, Kanika Trehan, et al.
American Journal of Respiratory and Critical Care Medicine|June 14, 2017
Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study ResultsNoah Lechtzin, Nicole Mayer-Hamblett, Natalie E West, et al.
Science Advances|April 25, 2017
Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalationCraig S Schneider, Qingguo Xu, Nicholas J Boylan, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
American Journal of Respiratory and Critical Care Medicine|August 31, 2017
Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease SeverityDeepika Polineni, Hong Dang, Paul J Gallins, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 24, 2018
CFTR modulator theratyping: Current status, gaps and future directionsJohn Paul Clancy, Calvin U Cotton, Scott H Donaldson, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 21, 2014
Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrierJung Soo Suk, Anthony J Kim, Kanika Trehan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Journal of Medical Genetics|December 13, 2006
Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in cystic fibrosisKitti Buranawuti, Michael P Boyle, Suzanne Cheng, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2011
N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticlesJung Soo Suk, Nicholas J Boylan, Kanika Trehan, et al.
American Journal of Respiratory and Critical Care Medicine|June 14, 2017
Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study ResultsNoah Lechtzin, Nicole Mayer-Hamblett, Natalie E West, et al.
Science Advances|April 25, 2017
Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalationCraig S Schneider, Qingguo Xu, Nicholas J Boylan, et al.
The New England Journal of Medicine|May 19, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, et al.
American Journal of Respiratory and Critical Care Medicine|August 31, 2017
Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease SeverityDeepika Polineni, Hong Dang, Paul J Gallins, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 24, 2018
CFTR modulator theratyping: Current status, gaps and future directionsJohn Paul Clancy, Calvin U Cotton, Scott H Donaldson, et al.
The New England Journal of Medicine|November 19, 2010
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutationFrank J Accurso, Steven M Rowe, J P Clancy, et al.
Pageof 10